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Abstract
Background. The COVID-19 pandemic has profoundly affected cancer services. Our objective was to determine the 
effect of the COVID-19 pandemic on decision making and the resulting outcomes for patients with newly diagnosed 
or recurrent intracranial tumors.
Methods. We performed a multicenter prospective study of all adult patients discussed in weekly neuro-oncology 
and skull base multidisciplinary team meetings who had a newly diagnosed or recurrent intracranial (excluding 
pituitary) tumor between 01 April and 31 May 2020. All patients had at least 30-day follow-up data. Descriptive sta-
tistical reporting was used.
Results. There were 1357 referrals for newly diagnosed or recurrent intracranial tumors across 15 neuro-oncology 
centers. Of centers with all intracranial tumors, a change in initial management was reported in 8.6% of cases 
(n = 104/1210). Decisions to change the management plan reduced over time from a peak of 19% referrals at the 
start of the study to 0% by the end of the study period. Changes in management were reported in 16% (n = 75/466) 
of cases previously recommended for surgery and 28% of cases previously recommended for chemotherapy 
(n = 20/72). The reported SARS-CoV-2 infection rate was similar in surgical and non-surgical patients (2.6% vs. 
2.4%, P > .9).
CovidNeuroOnc: A UK multicenter, prospective cohort 
study of the impact of the COVID-19 pandemic on the 
neuro-oncology service
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Conclusions. Disruption to neuro-oncology services in the UK caused by the COVID-19 pandemic was most 
marked in the first month, affecting all diagnoses. Patients considered for chemotherapy were most af-
fected. In those recommended surgical treatment this was successfully completed. Longer-term outcome 
data will evaluate oncological treatments received by these patients and overall survival.
Key Points
• 8.6% of patients with brain tumors received changes in treatment due to COVID-19.
• Overall rates decreased from 19% at the start of April 2020 to 0% by end May 2020.
• SARS-CoV-2 infection was not higher in patients undergoing surgery.
The severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) (COVID-19) pandemic has caused an unprec-
edented impact on the UK National Health Service (NHS). 
Major restrictions on resources and capacity have affected 
provision of both medical and surgical cancer therapies.1 
Cancer Research UK documented a 60% reduction in 
cancer surgery and an international study by the CovidSurg 
Collaborative reported that an estimated 2.3 million elec-
tive cancer cases had been cancelled worldwide.2,3 Delays 
to cancer surgery can impact on overall survival. A  three-
month delay across all stage 1 to 3 cancers is estimated to 
cause >4700 attributable deaths per year in England alone.4
Delaying surgical treatment of a brain tumor can lead 
to irreversible neurological impairment and be rapidly 
life-threatening because of the risk of raised intracranial 
pressure and coma. Two international reports from over 
90 countries, reported cancellation rates of up to 57.5% for 
neurosurgical operations and clinics across the globe.5,6 
Furthermore, there are considerable risks from surgery for 
patients with SARS-CoV-2 infection. An international pan-
specialty study by the CovidSurg Collaborative showed 
that in 1128 patients with a perioperative SARS-CoV-2 in-
fection, the mortality rate was 24% and 51% had pulmo-
nary complications.7
Guidance set out by the British Neuro-Oncology Society 
(BNOS) and the Society of British Neurological Surgeons 
(SBNS) on the 19th March 2020 made several recom-
mendations for surgical and oncological practice during 
the COVID-19 pandemic,8 including giving high surgical 
and oncology priority to patients with:
 •	Malignant gliomas suitable for surgery and adjuvant 
therapies.
 •	Posterior fossa tumors causing symptoms or 
hydrocephalus.
 •	Meningiomas causing major mass effect or neurolog-
ical deficit.
 •	Brain metastases suitable for surgery and 
supratentorial, or suitable for stereotactic radiosurgery 
or whole brain radiotherapy.
Conversely, low surgical and oncology priority were des-
ignated to patients with:
 •	Low-grade glioma where active monitoring is a reason-
able option.
 •	Skull base tumors where the patient was already 
planned for elective surgery.
 •	Radiotherapy for atypical/recurrent meningioma.
Guidelines regarding the overall surgical and adjuvant 
therapies for high-grade gliomas have also been published 
by an international consensus group.9
The COVID-19 pandemic presented several prob-
lems including how to maintain a safe surgical neuro-
oncology service, the risks posed to patients undergoing 
Importance of the Study
This study reports the effect that the COVID-
19 pandemic has imposed on clinical decision 
making within the UK neuro-oncology service. 
In 1210 consecutive patients with an intracranial 
tumor referred to their local neuro-oncology or 
skull base multidisciplinary team during the 
COVID-19 pandemic, 8.6% were recommended 
a management plan different to usual care. This 
affected 28% of patients who would have been 
usually offered chemotherapy and 16% of pa-
tients who would have been usually offered 
surgery. This study showed that the deviation 
from usual care was at its peak in April 2020 
(19%) and decreased to 0% change by the end 
of the study period (May 2020). SARS-CoV-2 in-
fection was not higher in patients undergoing 
surgery. Decisions relating to management of 
patients during the COVID-19 pandemic will 
be multifactorial and center-specific with con-
siderations to the presenting symptoms of the 
patient, local case incidence, and healthcare re-
source availability.











treatment, and how the decisions made by the neuro-
oncology multidisciplinary teams (MDT, a team of pro-
fessionals including neuro-oncologists, radiologists, 
neuropathologists, specialist nurses, and neurosur-
geons facilitating shared decision making between spe-
cialties—known as tumor board in North America) were 
affected. We therefore conducted the CovidNeuroOnc 
multicenter, prospective cohort study to assess the 
impact of the COVID-19 pandemic on the UK neuro-




CovidNeuroOnc is a national, multicenter, prospective ob-
servational study in the UK. We invited all adult neurosur-
gical units in the UK to collaborate on this study and 15 of 
32 participated. The study was designed and delivered by 
the British Neurosurgical Trainee Research Collaborative 
(BNTRC)10 and the Academic Committee of the Society of 
British Neurological Surgeons (SBNS).
Patient Identification
Consecutive patients were identified from weekly neuro-
oncology and skull base MDT (tumor board) meetings be-
tween 1st April and 31st May 2020 in participating units. All 
patients aged ≥16 years were included if they were found 
to have a newly diagnosed or recurrent intracranial tumor 
(including low-grade glioma, high-grade glioma, primary 
central nervous system lymphoma, meningioma, vestib-
ular schwannoma, or metastases) based on either com-
puted tomography (CT) or magnetic resonance imaging 
(MRI). Pituitary tumors were excluded from this study due 
to the possible endocrinological management and the sep-
arate MDT management of these tumors.
Data Collection
De-identified data were collected using a secure, online 
data collection tool (www.castoredc.com). Each local col-
laborator was given a unique account to facilitate an ac-
curate audit trail. Data fields included: age, sex, Eastern 
Cooperative Oncology Group (ECOG) performance status, 
date of MDT, and radiological diagnosis. We asked collab-
orators to record: (i) the “pre-COVID-19” MDT decision (the 
hypothetical decision of “usual” first line management that 
the MDT would have made without the influence of COVID-
19), and (ii) the “post-COVID-19” MDT decision, which is the 
first line management offered during the COVID-19 period. 
Sites recorded a single management option from the fol-
lowing: surgery (biopsy or resection), chemotherapy, frac-
tionated radiotherapy, stereotactic radiosurgery, active 
monitoring (watch and wait), no treatment required or best 
supportive care. A decision to delay or defer treatment was 
included when asking sites for “post-COVID-19” MDT de-
cisions. Data were also collected on the types and dates 
of treatments administered (surgery, chemotherapy, ra-
diotherapy, radiosurgery, active monitoring), and date of 
confirmed COVID-19 status (if applicable). Extent of re-
section was confirmed on postoperative MRI where it oc-
curred over the course of the study period. Date of death 
was also recorded for patients with suspected high-grade 
glioma based on MRI or confirmed high-grade glioma after 
surgery. SARS-CoV-2 infection was determined either by 
viral RNA detection (nose and throat swab) or by CT chest 
imaging as per the diagnostic process during the study 
period. Data collection was finalized on the 30th of June 
2020 to allow 30-day follow-up following the index MDT 
within the study period. All participating units attained 
local departmental approval as a service evaluation prior 
to anonymized data collection and submission such that in-
dividual consent was not required. Additional daily COVID-
19 confirmed cases were retrieved for temporal analysis 
from the UK government.11
Objectives
The primary objective was to determine whether the 
COVID-19 pandemic changed the management of patients 
with either newly diagnosed or recurrent intracranial tu-
mors, compared to usual care. Secondary objectives were 
to determine (i) how many patients did not receive sur-
gery, despite this being the MDT recommendation, (ii) how 
many patients contracted a SARS-CoV-2 infection, and (iii) 
how many patients with high-grade glioma died during the 
study period up to the first data lock on June 30, 2020.
Statistical Analysis
Categorical variables were reported as percentages. 
Continuous variables were reported as median and in-
terquartile range (IQR) or mean and standard deviation 
based on tests for normality with the Shapiro–Wilk test. 
Univariable categorical statistical tests were performed 
with Chi-square testing unless small samples sizes where 
Fisher’s exact testing was utilized. Odds ratios and 95% 
confidence intervals were computed using the Wald test. 
A  threshold P-value of <.05 was set to denote statistical 
significance. All analyses, tables, and graphics including 
Sankey diagrams were completed using the tidyverse, 
gtsummary, epitools, RColorBrewer, and riverplot pack-
ages in R v 3.6.0.12–16
Results
There were 1357 consecutive referrals for newly diagnosed 
or recurrent intracranial tumors across 15 regional neu-
rosurgical units in the United Kingdom between 1st April 
and 31st May 2020. Fourteen units provided data on all 
intracranial tumors, while one unit provided data on ma-
lignant gliomas only (n = 147). Data from this unit were ex-
cluded from total cohort summative statistic and included 
for specific analysis of malignant gliomas to optimize ex-
ternal validity. Descriptive statistics for the remaining 1210 
referrals are presented in Tables 1 and 2. The majority of 
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referrals were for newly diagnosed intracranial tumors 
(n = 950, 79%) and included patients aged 50–80 years old 
(n = 858, 71%) who were ECOG performance status 0 or 1 
(n = 862/1210, 71%). The most common referral of a new in-
tracranial tumor was for metastasis (n = 344, 36%) or high-
grade glioma (n = 295, 31%), whereas the most common 
recurrence was for glioma (n = 130/260, 50%, Table 2).
Primary Outcome
Overall, 8.6% of cases had a documented change in MDT 
decision compared to usual care (n = 104/1210). Figure 1 
shows the trends in weekly COVID-19 cases and number of 
referrals to the neuro-oncology MDT stratified by change in 
management. Changes in MDT decision were more likely 
in recurrent than newly diagnosed tumors (OR 1.8 95% CI 
1.2–2.8, P = .010). Over the study period, there was a signif-
icant reduction in the number of patients where COVID-19 
resulted in a change in management plan at the MDT. In 
the first week of the study, a change in MDT decision was 
seen in 19% (n = 23/120) of referrals, and this reduced to 0% 
(n = 0/82) by the end of May 2020. The majority of referrals 
with a change in MDT decision occurred in the first 4 weeks 
of the study period, which corresponded to the peak of the 
pandemic in the UK (n = 78/104, 75%).
The pre-COVID-19 and post-COVID-19 MDT decision 
are depicted in the Sankey diagram in Figure 2. The most 
common pre-COVID-19 management in all cases was sur-
gery (n  = 466, 39%). While a small proportion of patients 
were subject to a delay or deferral of treatment (n = 16, 1%), 
there was a larger proportion of patients where the MDT 
decision changed from surgical intervention. Of the 466 pa-
tients considered for surgery in pre-COVID-19 “usual care” 
decisions, 75 (16%) patients were instead offered alterna-
tive management plans including active monitoring (n = 28, 
37%), radiotherapy (n  =  18, 24%), best supportive care 
(n = 17, 23%), and a delay in treatment (n = 9, 12%). Of the 
72 patients considered for chemotherapy in pre-COVID-19 
decisions, 20 (28%) were subsequently offered alternatives, 
most commonly best supportive care (n = 13, 65%).
Given the large proportion of patients who would have 
been offered no treatment or best supportive care in a pre-
COVID-19 situation (n  =  235, 19%), these were excluded 
for the purpose of identifying factors resulting in a change 
in management as a result of COVID-19. Comparative de-
scriptive statistics of the remaining 975 referrals are shown 
in Table 3. There was no significant difference in age, sex, or 
ECOG, but patients presenting with a recurrence and in par-
ticular recurrent glioma were more likely to have a change 
in management plans (OR 3.3 95% CI 1.5–7.9, P  =  .003). 
Patients referred to the MDT with a suspected SARS-CoV-2 
infection at the time of MRI diagnosis were no more likely 
to be offered a change in management plan (P = .4).
Surgical Treatment
Descriptive statistics of all 354 patients who under-
went surgery up to 30th June 2020 are presented in the 
  
Table 1. Descriptive Statistics Stratified by Presentation (n = 1210)
Characteristic Overall, n = 1210 New Diagnosis, n = 950a Recurrence, n = 260a P-valueb
Age    <0.001
 16–19 5 (0.4%) 4 (0.4%) 1 (0.4%)  
 20–29 35 (2.9%) 26 (2.7%) 9 (3.5%)  
 30–39 66 (5.5%) 37 (3.9%) 29 (11%)  
 40–49 111 (9.2%) 73 (7.7%) 38 (15%)  
 50–59 256 (21%) 190 (20%) 66 (25%)  
 60–69 307 (25%) 253 (27%) 54 (21%)  
 70–79 295 (24%) 245 (26%) 50 (19%)  
 80–89 123 (10%) 110 (12%) 13 (5.0%)  
 90+ 12 (1.0%) 12 (1.3%) 0 (0%)  
Sex    0.2
 Female 619 (51%) 495 (52%) 124 (48%)  
 Male 591 (49%) 455 (48%) 136 (52%)  
ECOG    0.11
 0 466 (39%) 376 (40%) 90 (35%)  
 1 396 (33%) 294 (31%) 102 (40%)  
 2 204 (17%) 162 (17%) 42 (16%)  
 3 102 (8.5%) 84 (8.9%) 18 (7.0%)  
 4 29 (2.4%) 25 (2.7%) 4 (1.6%)  
aStatistics presented: n (%).
bStatistical tests performed: chi-square test of independence.
  











Supplementary Material (Supplementary Table S1). Of the 
391 patients with a plan for surgery following the MDT, 345 
(88%) were recorded to have undergone surgery, with 368 
operations performed in total. The majority of surgery per-
formed was for glioma (newly diagnosed n = 180/313, 58%, 
recurrent n = 21/41, 51%) and metastasis (newly diagnosed 
n  =  72/313, 23%, recurrent n  =  10/41, 24%). Surgical and 
histopathological data is provided in the Supplementary 
Material (Supplementary Table S2). No patient with an 
MDT plan for resection underwent a biopsy subsequently. 
Gross-total resection was achieved in 69% of cases where 
resection was planned in the MDT (n = 180/261).
Management of High-grade Glioma
Including all fifteen neuro-oncology units, 315 patients 
were referred with suspected high-grade glioma. The pre-
COVID-19 and post-COVID-19 MDT decisions are provided 
in the Supplementary Material (Figure 3). Overall, 23 (7%) 
patients with newly diagnosed high-grade glioma had a 
change in management as a result of COVID-19. Comparing 
with those without a change of management, patients 
offered an alternative management were more likely to be 
ECOG 2 (P = .017) but there was no difference in age (P = .6) 
or sex (P = .2). Of the 202 patients who would have been 
offered surgery as “usual care” before COVID-19, 11 (5%) 
were instead offered best supportive care, and 9 (4%) were 
offered fractionated radiotherapy without the need for a 
diagnostic biopsy. Of all 157 patients referred with recur-
rent glioma, 26 (17%) had a change in MDT decision be-
cause of COVID-19. There was no significant difference in 
  
Table 2. Descriptive Statistics of Most Likely Diagnosis Based on 
Radiological Imaging for Newly Diagnosed Intracranial Tumors and 
Original Histopathology for Recurrent Tumors (n = 1210)
New Diagnosis—Radiological Diagnosis n = 950a
High-grade glioma 295 (31%)




Primary CNS lymphoma 40 (4.2%)







Primary CNS lymphoma 3 (1.2%)
Vestibular schwannoma 6 (2.3%)
aStatistics presented: n (%).
b“Other” included chordoma, pineal tumor, ependymoma, 
ganglioglioma, and pineocytoma.
c“Other” included chordoma, chondrosarcoma, choroid plexus papil-























01 Apr 08 Apr 15 Apr 22 Apr 29 Apr 06 May 13 May 20 May 27 May
Change in management No Yes
Figure 1. MDT referrals by week stratified by primary outcome with overlay of weekly COVID-19 cases in the United Kingdom (n = 1210, note week 
commencing 27th May was 5 days).
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age (P = .2), sex (P = .7), or ECOG (P = .8) in the cohort of 
patients where a change in management plan was made. 
Of the 50 patients who would have been offered chemo-
therapy, 10 (20%) were instead offered best supportive 
care and a further 5 (10%) were recommended a delay in 
treatment. Further data is provided in the Supplementary 
Material (Figure 3).
Patients with newly diagnosed high-grade glioma sus-
pected on MRI who subsequently underwent surgery 
revealed 10 grade III gliomas, and 153 glioblastomas, 
while patients presenting with recurrence revealed 
1 recurrent grade III glioma and 16 recurrent GBM. 
Adjuvant treatment data for 162 high-grade glioma pa-
tients following surgery was available up to June 30, 
2020 (Supplementary Table S3). Of these, 54 (33%) were 
treated with adjuvant chemoradiotherapy, 12 (7%) with 
chemotherapy alone, 38 (23%) with radiotherapy alone, 
and 58 (36%) were treated with surgery without addi-
tional oncological treatment.
During the study period, of all 445 high-grade glioma 
patients (based on MRI or confirmed high-grade glioma 
after surgery), there were 25 (5.6%) deaths reported. Three 
deaths occurred within 30 days of surgery (on days 3, 11, 
and 17).
Management of Metastases
Including all 15 neuro-oncology units, 395 patients were 
referred with suspected cerebral metastases, of which, 314 
(79%) were referred with a known primary cancer. MDT de-
cisions are provided in the Supplementary Material (Figure 
3). Fifteen (8%) patients with newly diagnosed metastasis 
had a change in management. There was no significant dif-
ference in age (P = .9), sex (P = .5), or ECOG (P = .5) in the co-
hort of patients where a change in management plan was 
made. Stereotactic radiosurgery was the most common 
pre-COVID-19 management plan (n  =  109/395, 28%) 
whereas best supportive care was most common for post-
COVID-19 management (n  =  113/395, 29%). Including 89 
cases of recurrent cerebral metastasis, data on oncological 
treatment was available for 484 patients (Supplementary 
Table 4). Of these, the majority of patients underwent a 
single treatment (SRS n = 103/132 78%, surgery n = 43/80 
54%, radiotherapy n = 43/61 70%, chemotherapy n = 27/54 
50%). The most common combination therapy was surgery 
and SRS (n  =  14), followed by surgery and radiotherapy 
(n = 10). Patients with a recurrent metastasis were signif-
icantly more likely to receive chemotherapy for their sys-
temic disease (21% vs. 9%, P = .002).
Other Diagnoses
For patients with a radiological diagnosis of meningioma 
(n  =  157, 17%), the MDT decision changed because of 
COVID-19 for 16 (10%) patients. The most common man-
agement plan for patients with suspected meningioma was 
for active monitoring (n  = 84, 54%), followed by surgery 
(n = 50, 32%). Of those, 37 (74%) were recommended sur-
gery post-COVID-19 with 9 (18%) patients recommended 
active monitoring and 4 (8%) patients recommended a 
delay in treatment. Within the study period, 30 (81%) pa-
tients with meningioma had successfully undergone 
surgery.
Results were similar for patients with newly diagnosed 
low-grade glioma (n  =  60, 6%). MDT decisions changed 
due to COVID-19 for 10 (17%) patients. The most common 
pre-COVID-19 MDT plans were active monitoring (n = 29, 
48%) and surgery (n = 28, 47%). Ultimately 19 patients with 
suspected low-grade glioma were offered surgery post-
COVID-19, 7 (12%) were instead offered active monitoring 
and 2 (3%) patients were subject to a delay in planned 
treatment. Of available data for 18 patients, 16 had under-
gone surgery within the study period (89%).
SARS-CoV-2 Infections
Suspected and confirmed SARS-CoV-2 infection data 
were available for 1184/1210 patients (98%). The overall 
infection rate was 2.4% (29/1184). Of the 28 patients 
where mortality data was available, 8 patients died (29%), 
with 5 deaths directly attributed to SARS-CoV-2 infec-
tion. Diagnosis of SARS-CoV-2 was made using a swab 
in 25 cases, whereas in 3 cases diagnosis was made ra-
diologically and in one case it was unknown. Of the 348 
patients undergoing surgery, 9 (2.6%) developed a con-
firmed SARS-CoV-2 infection (Supplementary Table S1). 
Eight cases were diagnosed preoperatively, and the rate 
of infection was not significantly different to the cohort of 
patients developing SARS-CoV-2 not undergoing an oper-
ation (n = 20/826, 2.4%, OR 1.1 95% CI 0.5–2.3, P = .852). Of 
the overall deaths in patients with high-grade glioma, 5 
cases had a confirmed diagnosis of SARS-CoV-2, none of 
whom underwent surgery during the study period. In 3 of 
these cases, SARS-CoV-2 was documented as the primary 
cause of death.
Discussion
Change of MDT Recommendations During the 
COVID-19 Pandemic
This prospective, multicenter study reveals that during 
the height of the COVID-19 pandemic in the United 
Kingdom, a change in MDT decision making compared to 
“usual care” was recorded in 8.6% of cases. The reconfig-
uration of NHS services at the time included the decision 
on March 17, 2020 to postpone all non-urgent elective op-
eration from April 15, 2020 at the latest. During the first 
weeks of the study coinciding with the onset of national 
lockdown and reconfiguration of NHS services in April 
2020, the number of cases affected was as high as 19%. 
Two months later, while the lockdown and reconfigura-
tion persisted, there were no affected cases in the final 
recorded MDTs. Patients with recurrent glioma were most 
affected by the pandemic, principally because chemo-
therapy was withheld. The rate of recorded SARS-CoV-2 
infection during this period was low and was responsible 
for a small number of deaths recorded among patients 
with high-grade glioma.











Neuro-oncology services in the United Kingdom, sim-
ilar to other oncology services, altered practice during 
the COVID pandemic. The results are similar to a national 
survey of MDT decision making performed in 18 neuro-
oncology centers in the United Kingdom from 23rd March 
to 24th April 2020, where 10.7% of patients had their 
management changed as a result of the COVID-19 pan-
demic.17 A pan-cancer study by the UK Coronavirus Cancer 
Monitoring Project of 800 patients from 55 UK centers with 
a diagnosis of cancer (2% intracranial) showed that 22% 
of patients symptomatic of COVID-19 had a change of on-
cology management.18 In that cohort, management alter-
ations were directly influenced by confirmed SARS-CoV-2 
infection, whereas for our cohort, the suspicion of SARS-
CoV-2 infection at the time of the MRI diagnosis was not 
significantly associated with change of management. The 
wider effects of the COVID-19 pandemic and perceived in-
creased risk of death if patients were to become infected, 
are likely to have influenced decisions in our study.
Overall, 16% patients who would have been offered 
surgery as “usual care” were given a different recom-
mendation and 24% patients who would have previously 
been offered chemotherapy had a change in recommen-
dation. In the overall cohort we did not find that age or 
sex had a significant impact on MDT decision making. 
Although performance status was not associated with 
a change in management plan in the overall cohort, a 
poorer performance status did influence management 
recommendations in patients with a new diagnosis of 
a high-grade glioma. There was wide variation in the 
number of referrals received across units but this was 
due to a varying catchment population; all included 
units were offering regional services for patients with 
brain tumors.
There are 2 possible explanations to explain the reduc-
tion in changes in MDT decision making due to COVID-19 
over the course of the study. It may be that the disruption 
to the neuro-oncology services caused by the COVID-19 
pandemic was decreasing, or alternatively that neuro-
oncology services adapted to provide a service despite 
COVID-19 restrictions. It is notable that of the oncology 
treatment reported, a third of patients who underwent an 
operation have not been treated with adjuvant chemo-
therapy or radiotherapy at the time of writing. Despite 
the reported pre-COVID-19 recommendation being sur-
gery, 9% of patients with a radiologically defined, newly 
diagnosed high-grade glioma were offered best sup-
portive care or fractionated radiotherapy without a 
tissue diagnosis.
Surgical Management During the 
COVID-19 Pandemic
Comparing the practice observed to the published guide-
lines in March 2020, there has been a sustained delivery 
of surgical services for newly diagnosed high-grade 
glioma and metastasis with appropriate changes in MDT 
decisions to active monitoring for patients with low-
grade glioma and meningioma.8 Of the 391 patients who 
were recommended surgery, 345 (88%) underwent their 
operation in the 2 months of greatest disruption due to 
COVID-19 in the UK. Furthermore, a very small minority 
(2.6%) of patients treated surgically developed SARS-
CoV-2 and of these all but one was diagnosed preopera-
tively. This is a significant deviation from estimates and 
data published from the CovidSurg Collaborative where 
rates of cancellation in the 12 weeks of peak disruption 
were forecasted to be 37.7%, while rates of overall pre-
operative SARS-CoV-2 infection were 26% with a mor-
tality rate of 18.4% for neurosurgical procedures (overall 
mortality 26%). In our study where mortality of patients 
with high-grade glioma was recorded, 3 patients died as 
a result of SARS-CoV-2 none of whom received surgical 
treatment. The data presented in this study is encour-
aging with regards to the continued delivery of surgical 
neuro-oncology services in the UK.2,7 This is particularly 
















































































































Figure 2. Sankey diagram of change in management decision as 
a result of the COVID-19 pandemic (n = 1210). Delay = delay or defer 
treatment, Chemo = chemotherapy, RT = radiotherapy, SRS = stere-
otactic radiosurgery, Monitor = interval monitoring, None = no treat-
ment required, BSC = best supportive care.
  























































































































































Figure 3. Sankey diagram of change in management decision as a result of the COVID-19 pandemic for patients with newly diagnosed high-grade 
glioma (n = 315), recurrent glioma (n = 157), and newly diagnosed metastasis (n = 395). Delay = delay or defer treatment, Chemo = chemotherapy, 
RT = radiotherapy, SRS = stereotactic radiosurgery, Monitor = interval monitoring, None = no treatment required, BSC = best supportive care.
  











While initial guidance from UK8 and international9 
neuro-oncology experts has been published, it will be im-
portant to establish what overall treatment was provided 
to patients and perhaps consider a strategy for increasing 
the capacity of surgical neuro-oncology services and ease 
the pressures faced by local teams. Although nationally 
we managed to maintain surgical services for malignant 
brain tumors, a proportion of low-grade gliomas and me-
ningioma were recommended for interval MRI follow-up 
rather than early surgery.
Limitations
Our study has several limitations. Firstly, our primary out-
come is based on a hypothetical question asked in the 
neuro-oncology MDTs on what their recommendation for 
management would have been prior to the COVID-19 pan-
demic. The exact location of the tumor and presenting 
symptoms used for priority stratification in guidelines subse-
quently published during the pandemic was not collected, so 























































































































































Figure 3. Sankey diagram of change in management decision as a result of the COVID-19 pandemic for patients with newly diagnosed high-grade 
glioma (n = 315), recurrent glioma (n = 157), and newly diagnosed metastasis (n = 395). Delay = delay or defer treatment, Chemo = chemotherapy, 
RT = radiotherapy, SRS = stereotactic radiosurgery, Monitor = interval monitoring, None = no treatment required, BSC = best supportive care.
  
  
Table 3. Descriptive Statistics of Cohort Stratified by Whether MDT Recommended Management Changed as a Result of COVID-19 (n = 975)
Characteristic No, n = 871a Yes, n = 104a P-valueb
Age   .889
 16–19 4 (0.5%) 1 (1.0%)  
 20–29 31 (3.6%) 4 (3.8%)  
 30–39 58 (6.7%) 6 (5.8%)  
 40–49 94 (11%) 10 (9.6%)  
 50–59 210 (24%) 25 (24%)  
 60–69 243 (28%) 24 (23%)  
 70–79 190 (22%) 27 (26%)  
 80–89 41 (4.7%) 7 (6.7%)  
Sex   >.9
 Female 445 (51%) 52 (50%)  
 Male 426 (49%) 52 (50%)  
ECOG   .4
 0 388 (45%) 43 (42%)  
 1 317 (37%) 33 (32%)  
 2 129 (15%) 22 (22%)  
 3 24 (2.8%) 4 (3.9%)  
 4 4 (0.5%) 0 (0%)  
Presentation   .042
 New diagnosis 677 (78%) 71 (68%)  
 Recurrence 194 (22%) 33 (32%)  
New diagnosis—radiological diagnosis   .085
 High-grade glioma 193 (29%) 23 (32%)  
 Low-grade glioma 48 (7.1%) 10 (14%)  
 Meningioma 124 (18%) 16 (23%)  
 Metastasis 238 (35%) 14 (20%)  
 Other 34 (5.0%) 2 (2.8%)  
 Primary CNS lymphoma 30 (4.4%) 5 (7.0%)  
 Vestibular schwannoma 9 (1.3%) 1 (1.4%)  
Recurrence—original histopathology   .002
 Glioma 86 (44%) 24 (73%)  
 Meningioma 22 (11%) 3 (9.1%)  
 Metastasis 62 (32%) 1 (3.0%)  
 Other 17 (8.8%) 3 (9.1%)  
 Primary CNS lymphoma 2 (1.0%) 1 (3.0%)  
 Vestibular schwannoma 5 (2.6%) 1 (3.0%)  
SARS–CoV-2 suspected at time of MRI diagnosis 16 (1.8%) 3 (2.9%) .4
aStatistics presented: n (%).
b Statistical tests performed: chi-square test of independence; Fisher's exact test.
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guidelines. Therefore the generalizability of our findings 
is limited by context-specific factors during the COVID-19 
pandemic, including healthcare provider resource utiliza-
tion (including COVID-19 caseload) and staff sickness and 
subjective patient perception of safety in proceeding with 
admission to a hospital for treatment. Most of the change 
in management for newly diagnosed high-grade glioma 
occurred in older patients with poorer performance status, 
where we recommended for either best supportive care or 
radiotherapy (without tissue diagnosis). Pre-COVID many of 
these patients would have been offered surgery and radio-
therapy +/- chemotherapy, despite the fact that there is often 
limited benefit from active oncology treatment in terms of 
overall survival.19 These data will continue to be collected in 
this study in preparation for a second report on the longer-
term impact of COVID-19. Our patients had a minimum of 
only 30-days of follow up and it is likely that some patients 
may have gone on to have surgery outside of this follow-up 
window and are not captured in our analysis to date. These 
follow-up limitations are even more apparent when cap-
turing the data of patients who did or did not receive che-
motherapy or radiotherapy. This limitation will be mitigated 
with a planned second stage of data collection in July 2021 
in order to measure this in detail and also to measure sur-
vival data. Thirdly, data on the provision of chemotherapy 
and radiotherapy may have been impaired by the inability 
to collect data for patients treated outside of their tertiary 
neuro-oncology center. Similarly, our study may underesti-
mate the number of patients who contracted the COVID-19 
virus during the study period—particularly if they contracted 
it in a community setting. A factor that we were not able to 
determine from this study was the change of referral volume 
to the neuro-oncology MDTs. Results from another unpub-
lished survey of 30 UK neurosurgical units have shown a 
27% reduction in the number of patients discussed in the 
neuro-oncology MDTs. Wide variations in referrals have 
been reported for other cancers, and a multicenter prospec-
tive study from centers in England and Northern Ireland 
showed that in April 2020, compared to prepandemic data, 
urgent referrals for early cancer diagnoses were down by 
70–89%.1 A national report from Netherlands, reported an up 
to 26% reduction in cancer diagnosis and 60% reduction if 
skin cancer is included during the COVID-19 era.20
Conclusions
Our study demonstrates that the COVID-19 pandemic had a 
noticeable impact on the management recommendations 
made by UK neuro-oncology specialists in the early stages 
of the COVID-19 pandemic. Delivery of first-line surgical 
treatment for newly diagnosed malignant tumors was main-
tained consistent with published national guidance with a 
very low rate of postoperative SARS-CoV-2. However, for 
patients with newly diagnosed malignant tumors there was 
notable disruption of chemotherapy treatments, in particular 
for patients with recurrent high-grade glioma. Further inves-
tigation is required into the impact of COVID-19 on the provi-
sion of chemotherapy, radiotherapy, and other non-surgical 
therapies and ultimately on patient outcomes and survival.
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